Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
As repurposing ivermectin against Covid-19 is still in the focus of debates and as this drug can be formulated with
Aequus Pharmaceuticals Inc. and reVision Therapeutics, Inc. (“reVision”) announced a collaboration on the development of a therapy for Stargardt disease.
Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex
CBT-006 is a molecule developed by Cloudbreak Therapeutics that can sequester cholesterol. CBT-006 is a unique topical formulation following 505b(2)
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, announced that it has entered into an exclusive worldwide license agreement with